Testosterone in women: what the studies included

Reviewed 27 sourcesPublished by PepVault

Who the testosterone trials in women enrolled: menopause type, ages, estrogen use and dose, what each found, and where it is approved. Every trial in one table.

Grey-haired woman in a coral sports top curls dumbbells on a planted rooftop deck
Last reviewed
Sources
27
Questions
8
Compounds
1

The short answer

The testosterone trials in women enrolled mostly postmenopausal women under 70 whose low sexual desire distressed them, many after both ovaries were removed and already on estrogen. At doses that keep levels in the premenopausal range, testosterone added about one satisfying sexual event a month over placebo, with somewhat more acne and hair growth. No product is FDA-approved for women.

Every number checked at its primary source · · 27 sources · How we research

Evidence: Large randomized trials of the testosterone patch in postmenopausal women (447 to 814 women each, 24 to 52 weeks), a meta-analysis of 36 trials, and few or small trials before menopause; safety data stop at 24 months.

Grey-haired woman in a coral sports top curls dumbbells on a planted rooftop deck

Which women were in the testosterone trials?

Women make testosterone too, about half of it in the ovaries before menopause3. When researchers pooled every blinded trial of testosterone in women lasting at least 12 weeks, they found 36 trials with 8,480 participants1. The sexual-function results came from 15 trials in 3,766 postmenopausal women and only 3 trials in 226 premenopausal women18. A pooled analysis like this is a meta-analysis (pepvault.app/glossary/meta-analysis).

Most trials recruited women with hypoactive sexual desire disorder, HSDD: low desire for sex that has lasted and that bothers them, with no other cause such as depression or a strained relationship2. Within that group, the trials split three ways: surgical menopause, meaning both ovaries removed, usually with a hysterectomy; natural menopause; and whether the women were already taking estrogen. The answer a study gives depends on which of these women it enrolled.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's side-effect log takes acne, hair growth or any symptom you name, dated and rated by severity, so a change after starting is on record for the prescriber, not remembered.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Who did each trial enroll, and what did it find?

Most trials counted satisfying sexual events: sexual activity the woman herself rated satisfying, logged in a diary over four weeks. A crossover trial gives each woman both treatments in turn (pepvault.app/glossary/crossover-trial).

TrialWomenAgesMenopause and estrogenTrial doseFound
Shifren, NEJM 2000 (crossover)7531 to 56Surgical, on oral estrogenPatch, 150 or 300 mcg a day, 12 weeks each300 mcg raised sexual frequency and pleasure scores; free testosterone stayed within the normal range on average3
INTIMATE SM2 (Buster 2005)53320 to 70 eligibleSurgical, on estrogenPatch, 300 mcg a day, 24 weeks1.56 vs 0.73 more satisfying events per 4 weeks410
INTIMATE SM1 (Simon 2005)56226 to 70Surgical, on estrogenPatch, 300 mcg a day, 24 weeks2.10 vs 0.98 more per 4 weeks5
Braunstein 2005 (dose-finding)44724 to 70Surgical, on oral estrogenPatch, 150, 300 or 450 mcg a dayOnly 300 mcg beat placebo6
INTIMATE NM1 (Shifren 2006)54940 to 70 eligibleNatural, on oral estrogenPatch, 300 mcg a day, 24 weeks2.1 vs 0.5 more per 4 weeks711
APHRODITE (Davis 2008)81420 to 70 surgical, 40 to 70 natural (eligible)Surgical or natural, no estrogenPatch, 150 or 300 mcg a day, 52 weeks300 mcg: 2.1 vs 0.7 more per 4 weeks; 150 mcg not significant89
BLOOM-1 and BLOOM-2 (LibiGel)597 and 57530 to 65 eligibleSurgicalGel, 300 mcg a day, 24 weeksNo benefit over placebo; published only as abstracts122618
Davis, Ann Intern Med 200826135 to 46Premenopausal, low free testosteroneSpray: one 56 µL, one 90 µL or two 90 µL sprays a day, 16 weeksOnly the one 90 µL spray beat placebo: 2.48 vs 1.70 events per 28 days14
El-Hage 2007 (AndroFeme cream, crossover)36Average 54Hysterectomy, on estrogen patchesCream, 10 mg a day, 12 weeksSexual function score up 8.8 points, 44%1517

Doses are what each trial gave, told as that, not a dose for anyone. A patch delivers micrograms a day; a cream or gel is measured in milligrams applied, of which only part is absorbed.

Read down the found column and two things stand out. One dose, the 300 mcg patch, carried most of the evidence, in women with and without estrogen. And placebo helped a lot: women on placebo also had more satisfying events in every patch trial4578. The 2025 review for Australia's medicines subsidy committee noted that the two LibiGel trials, which found no benefit, sit outside the main meta-analysis because they were published only in abstract18.

How much did testosterone change sex drive?

Pooled across the postmenopausal trials, testosterone added 0.85 satisfying sexual events a month over placebo or a comparator, raised desire, arousal, orgasm and pleasure, and lowered distress about sex1. Desire moved by a standardized mean difference of 0.36, which puts different questionnaires on one scale: 0.2 is small and 0.5 moderate. The 2019 Global Consensus Position Statement, endorsed by eleven societies, rounds this to one event a month and gives it its top evidence grade2.

What it did not change matters as much. The same pooled data showed no effect on general wellbeing, mood, cognition, bone density, lean mass or strength, though few women contributed to those outcomes, and a small rise in weight12. The statement concludes that the only evidence-based use is postmenopausal women diagnosed with HSDD after a full assessment2.

Commonly reported: a slow start, with any change in desire showing after four to eight weeks17; oilier skin or a few spots; finer hairs thickening where the cream goes on; for some women, little felt at all by month three.

What did it do to cholesterol, skin and hair?

The route decided the cholesterol result. Testosterone taken by mouth raised LDL and lowered HDL, the protective kind; through the skin, by patch or cream, it left lipids unchanged over the trials' length12. Blood pressure, blood sugar and HbA1c did not rise2.

Skin and hair are the side effects that showed. The New Zealand data sheet for AndroFeme 1 pools the trials of products giving the same exposure:

Side effectTestosteronePlacebo
Increased hair growth8.6%6.1%
Acne7.5%5.0%
Hair loss4.5%4.4%
Voice change3.7%3.4%

Source for the table:17. The consensus statement calls the acne and hair growth mild and finds no link at these doses to hair loss, an enlarged clitoris or a deeper voice2. In APHRODITE, androgen effects, mostly unwanted hair, came to 30.0% on 300 mcg against 23.1% on placebo8.

PepVault's side-effect log takes acne, hair growth or any symptom you name, dated and rated by severity, so a change after starting is on record for the prescriber, not remembered. Log it in PepVault

When to get help A voice that starts to deepen, thinning hair on the scalp or a new breast lump is a reason to contact the prescriber rather than wait for the next check.

What about the breast and the heart?

In APHRODITE, four women on testosterone were diagnosed with breast cancer against none on placebo; one diagnosis came in the first four months and one woman had symptoms before she joined8. In open-label follow-up of the surgical-menopause trials, 967 women had 1,092 years of patch use between them, with three breast cancers, in line with the rate expected for their age16. The consensus statement finds no rise in breast density and no short-term effect on breast cancer risk, and says the trials are too short to judge the long term2.

For the heart, the pooled trials are short, and safety data at these doses stop at 24 months2. BioSante ran a safety trial of LibiGel in 3,656 women aged 50 and over with at least two heart risk factors, completed in 2012; no results are posted on its registry record13.

Who did the trials leave out?

  • Premenopausal women. Three small trials, so the consensus statement makes no recommendation for them182. A 2026 systematic review found two randomized trials in premenopausal women against seven in postmenopausal women24.
  • Women at high heart risk. The efficacy trials excluded them, and most enrolled women already on estrogen2.
  • Women with breast cancer in their history. Excluded from every HSDD trial2.
  • Women on antidepressants. APHRODITE excluded SSRIs; one trial of 44 women on SSRIs or SNRIs, 77% premenopausal, found more satisfying events918.
  • Women on oral conjugated estrogens. In the patch trials this subgroup did not improve significantly, and the AndroFeme 1 data sheet does not recommend use with them17.
  • Women without distress. Low desire that does not bother a woman is not HSDD, and Australia's subsidy committee judged that many trial women may not have met the full HSDD criteria18.

Is testosterone approved for women?

WhereStatus
United StatesNo FDA-approved indication for menopausal women; the FDA called a public workshop on it for September 17, 202620
European UnionIntrinsa patch (300 mcg a day) authorised July 28, 2006 for HSDD after both ovaries were removed, in women on estrogen; withdrawn May 25, 2012 at the maker's request, for commercial reasons19
AustraliaAndroFeme 1 cream registered November 23, 2020 for HSDD after menopause; a public subsidy was not recommended in November 202518
New ZealandAndroFeme 1 approved April 24, 2025; label starting dose 5 mg (0.5 mL) a day17
UK and South AfricaListed in the FDA's August 2026 notice as approving testosterone for HSDD in women; not confirmed on either regulator's own register20

In the US, prescribers use testosterone off-label (pepvault.app/glossary/off-label), and the guideline allows an approved male gel or cream, used with care at a dose suited to women21. Two drugs are FDA-approved for HSDD itself: flibanserin (Addyi) for women under 65, and bremelanotide (Vyleesi, PT-141) for premenopausal women2223; see pepvault.app/peptides/pt-141 and pepvault.app/peptides/for/libido.

Who decides, and what do the guidelines check?

The prescriber, with the woman. The guidelines set the frame: a full assessment for other causes first; a transdermal product that keeps total testosterone in the premenopausal range; no pellets or injections, which push levels above it, and no compounded products (pepvault.app/glossary/compounded), for want of efficacy and safety data221. A Spanish consensus published in November 2026 holds the same line and adds that use for energy, mood or wellbeing is not supported25.

Testosterone is not for use in pregnancy. The male products used off-label carry that on their labels: AndroGel's, for one, says it is contraindicated in pregnant women because testosterone can cause virilization of a female fetus27.

A blood level does not diagnose HSDD; it is a baseline for safety21. The consensus statement and the AndroFeme 1 label both check total testosterone before starting and 3 to 6 weeks in, then every 6 months, and stop treatment that brings no benefit by 6 months217. The tests to have before any hormone are in pepvault.app/guides/blood-tests-before-starting; testosterone in men is in pepvault.app/guides/raising-testosterone-trt-vs-others.

PepVault's bloodwork section keeps total and free testosterone, SHBG, LDL and HDL draw by draw. Its built-in testosterone range and "optimal" band are set for men, so type in the range printed on your own lab report and read the result against that range. Log it in PepVault

Track it in the app

Sources

  1. Islam RM et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019. PubMed 31353194
  2. Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019. PubMed 31498871
  3. Shifren JL et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000. PubMed 10974131
  4. Buster JE et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005. PubMed 15863529
  5. Simon J et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005. PubMed 16014407
  6. Braunstein GD et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med. 2005. PubMed 16043675
  7. Shifren JL et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause. 2006. PubMed 16932240
  8. Davis SR et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008. PubMed 18987368
  9. ClinicalTrials.gov. Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido (NCT00131495), Warner Chilcott. clinicaltrials.gov
  10. ClinicalTrials.gov. Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido (NCT00331214), Warner Chilcott. clinicaltrials.gov
  11. ClinicalTrials.gov. Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women (NCT00349791), Warner Chilcott. clinicaltrials.gov
  12. ClinicalTrials.gov. Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (NCT00613002), BioSante Pharmaceuticals. clinicaltrials.gov
  13. ClinicalTrials.gov. Safety and Efficacy of LibiGel for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women (NCT00612742), BioSante Pharmaceuticals. clinicaltrials.gov
  14. Davis S et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008. PubMed 18413618
  15. El-Hage G et al. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric. 2007. PubMed 17653960
  16. Nachtigall L et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011. PubMed 21142609
  17. Medsafe. AndroFeme 1 (testosterone) 10 mg/mL transdermal cream, New Zealand data sheet, revised August 14, 2026. medsafe.govt.nz
  18. Pharmaceutical Benefits Advisory Committee. Public Summary Document: testosterone 1% cream (AndroFeme 1), November 2025 PBAC meeting. prod3.pbs.gov.au
  19. European Medicines Agency. Intrinsa (testosterone): withdrawn EPAR. ema.europa.eu
  20. US Food and Drug Administration. Testosterone Use in Menopausal Women; Public Workshop; Request for Comments. Federal Register 91:53417, August 18, 2026. federalregister.gov
  21. Parish SJ et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021. PubMed 33814355
  22. Addyi (flibanserin) tablets, prescribing information. DailyMed. dailymed.nlm.nih.gov
  23. Vyleesi (bremelanotide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov
  24. Furlan VA et al. Testosterone therapy for female sexual dysfunction: a systematic review of the literature demonstrating outcomes in premenopausal and postmenopausal women. J Sex Med. 2026. PubMed 42430779
  25. Sánchez-Prieto M et al. GESS-AEEM consensus on testosterone therapy in women: a clinical implementation framework. Climacteric. 2026. PubMed 43056697
  26. ClinicalTrials.gov. Safety and Efficacy of LibiGel for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women (NCT00657501), BioSante Pharmaceuticals. clinicaltrials.gov
  27. AbbVie. AndroGel 1.62% (testosterone gel), prescribing information, sections 4 and 8.1. DailyMed. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo